Author:
Álvarez-Ossorio J.L.,Cozar-Olmo J.M.,Juárez-Soto Á.,Medina-López R.,Moreno-Jiménez J.,Requena-Tapia M.J.
Reference16 articles.
1. Mottet N, van den Bergh RCN, Briers E, Cornford P, de Santis M, Fanti S, et al. EAU-ESTRO-SIOG Guidelines on Pros-tate Cancer 2019 [consultado 9 Juk 2019]. Disponible en: https://uroweb.org/guideline/prostate-cancer/.
2. Trial design and objectives for castration-resistant prostate cancer: updated recommendations from the Prostate Cancer Clinical Trials Working Group 3;Scher;J Clin Oncol,2016
3. Screening older cancer patients: first evaluation of the G-8 geriatric screening tool;Bellera;Ann Oncol,2012
4. Castrate resistant prostate cancer. Consensus recommendations of the Spanish Association of Urology;Loizaga-Iriarte;Actas Urol Esp,2017
5. Abiraterone acetate plus prednisone versus placebo plus prednisone in chemotherapy-naive men with metastatic castration-resistant prostate cancer (COU-AA-302): final overall survival analysis of a randomised, double-blind, placebo-controlled phase 3 study;Ryan;Lancet Oncol,2015